Submitted by kBLASTER Team on
Bern, SWITZERLAND (May 8, 2015) – CAScination AG, a Swiss medical device company, announces FDA 510(k) clearance of its unique, award-winning surgical navigation system for open liver surgery. Being a pioneer in surgical navigation for soft organs, CAScination guides surgical instruments for effective tumor removal while sparing healthy parts of the liver. The CAS-ONE LIVER device (CE marked since 2010) is in active use in leading European cancer centers and has enhanced treatments for hundreds of patients.
CAScination’s highly intuitive surgical navigation system with unique ultrasound fusion technology offers guidance for a wide range of surgical instruments and ablation devices. It provides surgeons with a clinically relevant tool to target small tumors and to identify structures at risk. This enables treatment of complex and advanced liver disease where high tumor load and critical tumor location demand a sophisticated surgical technique.
CAS-ONE LIVER uses world-leading surgery planning provided by CAScination’s partner MeVis Medical Solutions and enables fusion with intra-operative ultrasound imaging. Using infrared-based instrument tracking, the position and orientation of surgical instruments relative to internal anatomy is calculated and displayed in real time alongside a virtual 3D representation of the patient’s anatomy. This guides surgeons to relevant treatment locations and provides an accurate overview of the anatomical situation.
Looking for the cornerstone to a successful 510(k) clearance strategy? kBLASTER® FDA 510(k) search can quickly identify the best available primary predicate, multiple predicates or reference devices and manage those results effectively.